Cannabidiol News and Research

Latest Cannabidiol News and Research

The pluses and minuses of allowing medical marijuana at school

Every school day at noon, Karina Garcia drives to her son’s South San Francisco high school to give him a dose of cannabis oil to prevent potentially life-threatening seizures.

30 Aug 2018

Component of cannabis could help in psychosis

Researchers from King’s College London have now found how the chemical cannabidiol or CBD from cannabis can reduce the abnormal brain activity in patients who are at risk of psychosis. The study was published in the latest issue of the journal JAMA Psychiatry.

30 Aug 2018

New review examines potential of medicinal cannabis to help treat intractable epilepsy

A new British Journal of Clinical Pharmacology review examines the potential of medicinal cannabis--or medical marijuana--for helping patients with intractable epilepsy, in which seizures fail to come under control with standard anticonvulsant treatment.

8 Aug 2018

Research sheds light on composition of cannabis used to treat children with epilepsy

A pioneering study has found Australian parents who turned to medicinal cannabis to treat children with epilepsy overwhelmingly (75 percent) considered the extracts as "effective". Contrary to parental expectations, extracts generally contained low doses of cannabidiol - commonly considered to be a key therapeutic element and that has been successfully used in recent clinical trials to treat epilepsy.

5 Jul 2018

FDA approves cannabis based drug for severe form of epilepsy

The U.S. Food and Drug Administration (FDA) on the 25th of June 2018 approved Epidiolex oral solution that is essentially cannabidiol or the active component of marijuana or cannabis. As of now the drug is approved for use in two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome. The approval comes for individuals over two years of age.

28 Jun 2018

FDA approves new marijuana-based drug to treat rare and severe forms of epilepsy

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

25 Jun 2018

FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies

A new partnership between FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological diseases based at RCSI and GreenLight Medicines, an indigenous Irish biopharmaceutical company has been formed to develop new cannabis-based treatments for drug-resistant epilepsies, and in particular, childhood epilepsies.

17 May 2018

Study to examine whether cannabidiol provides therapeutic benefit to children with autism

Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol, a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder.

27 Apr 2018

Studies show hemp's potential for treating ovarian cancer

Results from some of the first studies to examine hemp's ability to fight cancer show that it might one day be useful as plant-based treatment for ovarian cancer. Hemp is part of the same cannabis family as marijuana but doesn't have any psychoactive properties or cause addiction.

24 Apr 2018

Study provides guidance on using cannabis for treatment of stress, anxiety, and depression

In a first-of-a-kind study, Washington State University scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home.

20 Apr 2018

FDA approves marijuana based medication for epilepsy treatment

An advisory panel from the United States Food and Drug Administration (FDA) has recommended the approval of a novel epilepsy drug that is made up of ingredients from marijuana. The agency normally follows the recommendations of the advisory panels regarding approvals and rejections of applications of new drugs. The recommendation statement came yesterday (19th April 2018).

19 Apr 2018

Non-psychoactive cannabis ingredient could reduce risk of relapse among recovering addicts

A preclinical study in rats has shown that there might be value in using a non-psychoactive and non-addictive ingredient of the Cannabis sativa plant to reduce the risk of relapse among recovering drug and alcohol addicts.

23 Mar 2018

Cannabis use triggers schizophrenia and other psychiatric issues

Schizophrenia and other psychiatric issues may be triggered by marijuana use, according to a research analysis in the Journal of the American Osteopathic Association.

12 Feb 2018

Major labeling inaccuracies in cannabidiol extract products

There is a growing demand among consumers for marijuana containing products supposedly providing several health benefits in a range od diseases and conditions. This has spawned thousands of websites that are selling these products online. Many of these contain mislabeled cannabidiol (CBD) or a compound found in cannabis or marijuana finds a new study.

7 Nov 2017

Study finds mislabeling in nearly 70% of cannabidiol products sold online

In recent years, there has been an increased interest in the medicinal use of Cannabidiol (CBD), a chemical that naturally occurs the in cannabis plant (aka "marijuana"). There is interest in CBD as a medicine because there is some evidence that it has medical benefits,

7 Nov 2017

Mislabeling of cannabidiol products poses safety and efficacy issues for consumers

Growing consumer demand for cannabis-related products purported to have medicinal benefits has created an environment where people are using mislabeled cannabidiol products sold online.

7 Nov 2017

FDA issues warning letters to companies illegally selling products that claim to cure cancer

As part of the U.S. Food and Drug Administration's ongoing efforts to protect consumers from health fraud, the agency today issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these outcomes.

2 Nov 2017

FDA warning on miracle marijuana cures for cancer

Yesterday, 1st November 2017, the U.S. Food and Drug Administration, FDA, released a statement warning the general public against fraudulent claims regarding marijuana based cancer cures. The FDA has also issued warnings in writing to four companies that are selling such products online illegally. These products are being advertised as miracle cures for cancers and several serious conditions.

2 Nov 2017

Systematic review finds lack of data on medical cannabis use in children and adolescents

A systematic review of published studies on the use of medical cannabis in children and adolescents finds a notable lack of studies and a minimal number of the randomized, controlled trials needed to confirm the effectiveness of a treatment.

23 Oct 2017

Cannabidiol appears to protect against long-term negative psychiatric effects of THC

A study reported Sept. 5 by neuroscientists at Indiana University finds that a non-psychoactive compound in cannabis called cannabidiol, or CBD, appears to protect against the long-term negative psychiatric effects of THC, the primary psychoactive ingredient in cannabis.

6 Sep 2017

Cannabidiol News and Research

Latest Cannabidiol News and Research

The pluses and minuses of allowing medical marijuana at school

Component of cannabis could help in psychosis

New review examines potential of medicinal cannabis to help treat intractable epilepsy

Research sheds light on composition of cannabis used to treat children with epilepsy

FDA approves cannabis based drug for severe form of epilepsy

FDA approves new marijuana-based drug to treat rare and severe forms of epilepsy

FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies

Study to examine whether cannabidiol provides therapeutic benefit to children with autism

Studies show hemp's potential for treating ovarian cancer

Study provides guidance on using cannabis for treatment of stress, anxiety, and depression

FDA approves marijuana based medication for epilepsy treatment

Non-psychoactive cannabis ingredient could reduce risk of relapse among recovering addicts

Cannabis use triggers schizophrenia and other psychiatric issues

Major labeling inaccuracies in cannabidiol extract products

Study finds mislabeling in nearly 70% of cannabidiol products sold online

Mislabeling of cannabidiol products poses safety and efficacy issues for consumers

FDA issues warning letters to companies illegally selling products that claim to cure cancer

FDA warning on miracle marijuana cures for cancer

Systematic review finds lack of data on medical cannabis use in children and adolescents

Cannabidiol appears to protect against long-term negative psychiatric effects of THC

Cannabis Testing & Analysis eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Cannabidiol News and Research

Latest Cannabidiol News and Research

Cannabis Testing & Analysis eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in